Procurement Summary
Country : Brazil
Summary : Potential Acquisition of Non -Standard Drugs Belonging to Groups: 0936 - Registered Medicines of Specific Purchase; 09.N.03.A - Antiepileptics; and 09.A.10.A - Insulin and Analogs, a ...
Deadline : 14 Apr 2025
Other Information
Notice Type : Tender
TOT Ref.No.: 117093870
Document Ref. No. : 90086/2025
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Object: Electronic Auction - Potential acquisition of non -standard drugs belonging to groups: 0936 - registered medicines of specific purchase; 09.n.03.A - Antiepileptics; and 09.a.10.A - Insulin and analogs, in order to meet the judicial determinations to the detriment of the Secretariat ofHealth State of the Federal District (SES/DF), according to specifications and quantities contained in Annex I of the Notice.
UASG Code: 926119
Notice from: 01/04/2025 from 08:00 to 12:00 and from 13:00 to 17:00
Proposal Delivery: From 01/04/2025 to 08:00
Cabazitaxel, concentration40 mg/ml, pharmaceutical form injectable solution
Quantity: 36
clonazepam, dosage 2 mg
quantity: 1080
insulin, type of fast action, concentration 100 IU/ml, pharmaceutical form injectable solution, additional with application system
quantity: 72
cyclosporine, concentration 0.5 mg/ml, formPharmaceutical Emulsion Ophthalmic
Quantity: 4320
Insulin, Aspart Origin, concentration 100 UI/ml, pharmaceutical form injectable solution, additional characteristic with applicator
Quantity: 396
Natalizumab, concentration 20 mg/ml, pharmaceutical form injectable solution
Quantity
Natalizumab, Concentration 20 mg/ml, pharmaceutical form injectable solution
Quantity: 135
nintedanib, composition sillet, concentration 100 mg
quantity: 4860
nintedanib, composition silet, concentration 100 mg
quantity: 1620
lanreotida acetate, concentration 180 mg/ml, pharmaceutical form solutionInjectable, additional characteristics prolonged release
Quantity: 27
lanreotide acetate, concentration 180 mg/ml, pharmaceutical form injectable solution, additional characteristics prolonged release
Quantity:9
Documents
Tender Notice